What it is: A highly potent synthetic growth hormone-releasing peptide that also has a unique line of cardiac biology research involving direct receptor binding in heart tissue.
Research suggests: Produces among the strongest GH pulses of any GHRP studied; animal and limited human research suggests cardioprotective mechanisms that operate independently of GH.
Best for: GH stimulation and cardiac biology researchers
Key thing to know: Tachyphylaxis — receptor desensitization with repeated use — occurs quickly; the GH response diminishes substantially without breaks, which is why alternating on and off periods is discussed in the research.
What is Hexarelin?
Hexarelin (INN: Examorelin) is a synthetic hexapeptide growth hormone-releasing peptide, one of the most potent GHRPs developed in research. It belongs to the same peptide family as GHRP-6 and Ipamorelin but is distinguished by its GH-stimulating potency and by research into cardioprotective mechanisms that appear to operate entirely independently of its GH-releasing activity.
Researchers study hexarelin primarily for growth hormone stimulation, body composition improvement, and its unique cardiac receptor activity. The cardioprotective angle, involving direct binding to CD36 receptors in cardiac tissue, represents a separate research dimension from its pituitary GH activity and has generated independent scientific interest beyond the GH secretagogue category.
How it works.
In research, the proposed mechanism has several parts.
Ghrelin receptor: Hexarelin's primary mechanism is ghrelin receptor (GH secretagogue receptor, GHS-R) agonism in the pituitary, triggering robust GH release. Its GH-stimulating effect is among the strongest of any GHRP, with GH levels exceeding other GHRPs at equivalent doses. It is less selective than newer compounds like Ipamorelin, co-elevating cortisol and prolactin more.
What is distinctive: What makes hexarelin distinctive is evidence that it also binds CD36, a scavenger receptor in cardiac and vascular tissue, producing direct cardiac effects independent of GH. In preclinical studies, it has been associated with reduced cardiac fibrosis, improved left-ventricular function, and protection from ischemia-reperfusion injury — a second mechanism separate from its pituitary action.
Desensitization: Continuous hexarelin use has been documented to desensitize the GHS-R, attenuating GH response over time. The research literature discusses alternating on and off periods as one approach studied to maintain GH response, though parameters in humans have not been formally established.
What the research shows.
Human pharmacokinetic and pharmacodynamic data confirm that hexarelin produces significant and reproducible GH pulses in healthy subjects, with some studies demonstrating GH responses exceeding those of GHRP-6 and other comparators at equivalent doses. This GH-stimulating evidence is well-established in the human literature.
The cardioprotective evidence base is compelling but currently rests mainly on preclinical studies and small human studies in cardiac-dysfunction populations. CD36-mediated cardiac protection has been shown consistently in rodent ischemia models and in patients with severe heart failure, where hexarelin improved cardiac output independent of GH. These findings are significant but require larger prospective human outcome trials.
Biomarkers to review first.
IGF-1 monitoring is mandatory before and during any hexarelin protocol. Given its cortisol and prolactin elevation profile, these markers are also relevant baseline considerations.
What it's commonly researched with.
Hexarelin is most often studied alongside GHRH analogs that target a complementary step in the GH secretion cascade, amplifying GH output through a synergistic dual-pathway approach. These combinations represent what appears in the research literature, not recommendations for use.